Save the Date: Targeting the Pathway: Evolving Roles of MEK Inhibitors in NF1-Associated PN

Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform neurofibromas (PNs), which can cause significant morbidity due to pain, disfigurement, neurologic impairment, and risk of malignant transformation. Despite advances in understanding NF1 biology, care remains complex and often fragmented across specialties, leading to delayed recognition and limited access to evolving therapies. Recent clinical evidence has established MEK inhibitors as targeted therapeutic options for NF1-associated PNs. Incorporating these therapies into practice requires careful patient selection, safety monitoring, and interprofessional coordination to ensure optimal outcomes.

This CE Concepts livestream symposium will address these critical gaps by equipping neuro-oncologists, neurosurgeons, radiation oncologists, medical oncologists, advanced practitioners, and nurses with strategies for early recognition of NF1-associated tumors, effective integration of MEK inhibitors, and development of evidence-based, interprofessional care plans that support individualized, longitudinal management.

At the conclusion of this activity, learners will be able to better:

• Assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making
• Integrate MEK inhibitors in the management of NF1-associated PNs in adult and pediatric patients
• Develop evidence-based, interprofessional care plans for patients with NF1 that reflect current clinical standards and support individualized, longitudinal management

This program is supported through an independent educational grant from Alexion Pharmaceuticals.

Neuro-oncologists, neurosurgeons, radiation oncologists, medical oncologists, physician associates (PAs), nurse practitioners (NPs), and nurses

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Blakeley reports the following financial relationships:

Consultant: Alexion Pharmaceuticals, Inc. and SpringWorks Therapeutics, Inc.

Research Support: Bristol Myers Squibb Company

Dr. Hargrave reports the following financial relationships:

Advisory Board and Consultant: Alexion Pharmaceuticals, Inc./AstraZeneca; Day One Biopharmaceuticals, Inc.; Ipsen Pharma; Novartis; and SpringWorks Therapeutics, Inc.

Grants: Alexion/AstraZeneca

Speakers Bureau: Alexion Pharmaceuticals, Inc./AstraZeneca; Ipsen Pharma; and SpringWorks Therapeutics, Inc.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Jessica Giddens, DNP, APRN, FPMHNP-BC, RN-BC (Peer Reviewer)
Thomas Mitchell, MSW, LSW (Planning Committee)
Nichole Lainhart (Planning Committee)
David Modrak, PhD (Planning Committee)
Alexis Oneca (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.